In the Annual Completed Clinical Trials Report 2026, uncover the critical signals shaping the future of drug development. By analyzing year-on-year shifts in completed trials, this report reveals how therapy areas are evolving, where momentum is building across trial phases, and which sponsors and outcomes are redefining the competitive landscape. Because when you understand what’s just concluded, you gain the clearest view of what comes next.
Drew Muscara
Trialtrove Analyst | Citeline
View profile
Trialtrove Analyst | Citeline
Drew currently supports clinical trial intelligence for the cardiometabolic, vaccine, infectious disease, and genitourinary therapy areas at Citeline. He excels in conducting in-depth data analyses for a variety of applications and utilizes these methods in constructing detailed Ask the Analyst responses. Additionally, through his membership on our analyst bench team, Drew has assisted on a variety of bespoke consulting projects to serve clients. Prior to joining Citeline in 2021, he also conducted research in immunology, lupus, and cell apoptosis. The study focused on determining relative gene expression in cell culture derived from animals that had contracted lupus.
Alexander Noll
Trialtrove Analyst | Citeline
View profile
Trialtrove Analyst | Citeline
Alexander currently supports clinical trial intelligence for the autoimmune, central nervous system, and ophthalmology therapeutic areas at Citeline. On the analyst bench, he has assisted with projects focused on pipeline analysis/ visualization and the epidemiology of rare diseases. Prior to joining Citeline, he worked at the University of Minnesota, conducting preclinical and clinical research on chronic pain. He has a bachelor’s degree in neuroscience and a master’s degree in pharmacology from the University of Minnesota.
